Digest Network Come funziona
Network
/
Società
Vi
Non verificato

ViiV Healthcare

Di cosa scriviamo

FarmaceuticaHIV, AIDS e malattie autoimmuniIndustriaMedicina - VarieSalute

25 comunicati stampa

Guarda tutti i comunicati
29/07/2026
Eventi
HIV, AIDS e malattie autoimmuni
Salute
Medicina - Varie
Scienza
Farmaceutica
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
27/07/2026
Eventi
Industria
HIV, AIDS e malattie autoimmuni
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
21/07/2026
Eventi
Industria
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Salute
Farmaceutica
Sanità
ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
01/06/2026
PrEP Wisdom: ViiV Healthcare Launches New Campaign to Support Informed HIV Prevention Choices
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
10/04/2026
Industria
Biotecnologia
Farmaceutica
HIV, AIDS e malattie autoimmuni
Giovani
Salute
Vetrine/Shopping
The Time to Talk about HIV is Now: ViiV Healthcare Launches "Still Here" PSA to Ignite Action Around HIV on National Youth HIV/AIDS Awareness Day
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
25/02/2026
Industria
HIV, AIDS e malattie autoimmuni
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
25/02/2026
Eventi
Fiere
Industria
HIV, AIDS e malattie autoimmuni
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
18/02/2026
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Biotecnologia
Sanità
Farmaceutica
Salute
Industria
ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
17/02/2026
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
HIV, AIDS e malattie autoimmuni
Salute
Medicina - Varie
ViiV Healthcare showcases long-acting HIV innovation and potential of ultra long-acting pipeline, including new data for first third-generation integrase inhibitor at CROI 2026
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0
17/10/2025
Biotecnologia
Farmaceutica
HIV, AIDS e malattie autoimmuni
Sanità
Salute
Igiene alimentare
Medicina - Varie
Industria
ViiV Healthcare announces 96-week data reaffirming Dovato is as effective as Biktarvy in maintaining virological suppression of HIV-1 with significantly less weight gain
Fonte
ViiV Healthcare
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0